scispace - formally typeset
M

Massimiliano Todisco

Researcher at University of Pavia

Publications -  26
Citations -  365

Massimiliano Todisco is an academic researcher from University of Pavia. The author has contributed to research in topics: Swallowing & Dysphagia. The author has an hindex of 8, co-authored 26 publications receiving 161 citations. Previous affiliations of Massimiliano Todisco include University of Würzburg.

Papers
More filters
Journal ArticleDOI

COVID-19 and Guillain–Barré Syndrome: A Case Report and Review of Literature

TL;DR: A review of the 29 articles so far published, describing 33 GBS cases and five MFS cases associated with SARS-CoV-2 infection recommends awareness of this rare, but treatable, neurological syndrome, which may also determine a sudden and otherwise unexplained respiratory deterioration in COVID-19 patients.
Journal ArticleDOI

Neuropathological findings from COVID-19 patients with neurological symptoms argue against a direct brain invasion of SARS-CoV-2: A critical systematic review.

TL;DR: In this paper, a systematic literature review on neuropathological studies in COVID-19, including 438 patients from 45 articles published by April 22, 2021, retrieved quantitative data regarding demographic, clinical, and neuropathology findings.
Journal ArticleDOI

Effects of More-Affected vs. Less-Affected Motor Cortex tDCS in Parkinson's Disease.

TL;DR: The findings support the potential usefulness of tDCS as add-on treatment for asymmetric PD, also providing interesting clues on the possible pathophysiological role played by an asymmetric activation of homologous motor cortical areas in PD.
Journal ArticleDOI

Botulinum toxin is effective in the management of neurogenic dysphagia. clinical-electrophysiological findings and tips on safety in different neurological disorders

TL;DR: Findings confirm the effectiveness of IncobotulinumtoxinA injection in the treatment of neurogenic dysphagia due to hyperactivity and relaxation failure of the UES and should be used as regards, the re-injection in non-responders to the first treatment.